Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dificid

- PMLiVE

FDA green lights rapid coronavirus diagnostic test

Test can diagnose positive cases in approximately 45 minutes

- PMLiVE

FDA maintains COVID-19 therapeutics must meet a ‘gold standard’

Comes after President Trump called for expedited approval of potential treatments

- PMLiVE

Trump calls on FDA to cut ‘red tape’ as coronavirus drug trials gather pace

A number of candidates begin trial testing

- PMLiVE

Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win

New-generation shot could protect franchise from rival Merck & Co

- PMLiVE

Lilly partners with Indiana State Health Department for coronavirus testing

Experts maintain that testing can curb the outbreak

- PMLiVE

FDA knocks back DBV’s peanut allergy therapy once again

Drug loses further ground to Aimmune's Palforzia

- PMLiVE

Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer

Checkpoint inhibitor unlikely to improve progression-free survival

- PMLiVE

FDA green lights study of phage-based drug for resistant infections

Possible alternative to conventional antibiotics

Roche Basel Switzerland

FDA okays Roche’s COVID-19 diagnostic test

Increases capacity for testing as coronavirus cases grow

AstraZeneca AZ

AZ’s comeback drug cediranib stumbles in phase 3 trial

Failed to improve on platinum-based chemotherapy

- PMLiVE

NHS increases COVID-19 testing capacity, FDA halts foreign inspections

New measures to tackle the novel coronavirus announced across the Atlantic

- PMLiVE

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

Potential treatment for patient group with no FDA-approved drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links